|
Showing 1 - 3 of
3 matches in All Departments
The drug discovery and development process is getting longer, more
expensive, and no better. The industry suffers from the same
clinical attrition and safety-related market withdrawal rates today
as it did 20 years ago. Industrialization of Drug Discovery: From
Target Selection Through Lead Optimization scrutinizes these
problems in detail, contrasting the promise of technology and
industrialization with the challenges of using the tools available
to their best advantage. The book explores early successes,
examines the current state of the art, and provides a strategic
analysis of the issues currently facing drug discovery. Introducing
the historical background and current status of the industry, the
book delineates the basic tenets underlying modern drug discovery,
how they have evolved, and their use in various approaches and
strategies. It examines, in detail, the regulations, requirements,
guidelines, and draft documents that guide so many FDA actions. The
editor devotes the remainder of the discussion to
industrialization, compound and knowledge management functions, the
drug screening process, collaboration, and finally, ethical issues.
Drawing on real-life, from-the-trenches examples, the book
elucidates a new approach to drug discovery and development. This
modern-day, back-to-basics approach includes three steps:
understand the science, unravel the story, and then intelligently
apply the technology, bringing to bear the entire armamentarium of
industrialization techniques, not just automation, to the discovery
process. Using these steps, you can meet the goals of more specific
targets, more selective compounds, and decreased cycle times. In
effect, you can look for a bigger needle in a smaller haystack.
Daniel E. Levy, editor of the Drug Discovery Series, is the founder
of DEL BioPharma, a consulting service for drug discovery programs.
He also maintains a blog that explores organic chemistry.
The biopharmaceutical industry has entered an era of unprecedented
change and challenge, characterized by increasing pricing
pressures, rising rates of attrition in the product development
lifecycle, and decreasing scientific innovation. The most
successful products are losing patent protection, and pipelines
have been unable to fill the gap. This book explores the evolving
definition of innovation in therapeutic product development and
begins to examine its effects on the life sciences R&D
industry. Historically, scientific innovation alone was sufficient
to maintain ROI and deliver on unmet medical needs. However, with
many forces now conspiring to increase pressures on the
commoditization of drug development, industry support for truly
novel, often high-risk development has eroded. This calls for a
drastic redefinition of what "innovation" is. While innovation in
the pharmaceutical R&D industry has historically been applied
to major advances in therapy and unmet medical needs, we now need
to see innovation increasingly defined in terms of financial,
marketing (e.g. branded generics and emerging markets),
pharmacoeconomic, and operational innovation. In this book,
contributors drawn from the executive ranks of clinical development
practitioners and stakeholders-from biopharmaceutical companies,
clinical research organizations, academia, the financial community,
and the patient perspective-have all come together to provide their
expertise and visions. Their goal is to start a dialogue about ways
to radically improve therapeutics development and get more and
better medicines to the patients who need them, as fast as
possible, in the most cost-efficient manner.
The drug discovery and development process is getting longer, more
expensive, and no better. The industry suffers from the same
clinical attrition and safety-related market withdrawal rates today
as it did 20 years ago. Industrialization of Drug Discovery: From
Target Selection Through Lead Optimization scrutinizes these
problems in detail, contrasting the promise of technology and
industrialization with the challenges of using the tools available
to their best advantage. The book explores early successes,
examines the current state of the art, and provides a strategic
analysis of the issues currently facing drug discovery. Introducing
the historical background and current status of the industry, the
book delineates the basic tenets underlying modern drug discovery,
how they have evolved, and their use in various approaches and
strategies. It examines, in detail, the regulations, requirements,
guidelines, and draft documents that guide so many FDA actions. The
editor devotes the remainder of the discussion to
industrialization, compound and knowledge management functions, the
drug screening process, collaboration, and finally, ethical issues.
Drawing on real-life, from-the-trenches examples, the book
elucidates a new approach to drug discovery and development. This
modern-day, back-to-basics approach includes three steps:
understand the science, unravel the story, and then intelligently
apply the technology, bringing to bear the entire armamentarium of
industrialization techniques, not just automation, to the discovery
process. Using these steps, you can meet the goals of more specific
targets, more selective compounds, and decreased cycle times. In
effect, you can look for a bigger needle in a smaller haystack.
Daniel E. Levy, editor of the Drug Discovery Series, is the founder
of DEL BioPharma, a consulting service for drug discovery programs.
He also maintains a blog that explores organic chemistry.
|
You may like...
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
Loot
Nadine Gordimer
Paperback
(2)
R398
R330
Discovery Miles 3 300
Poor Things
Emma Stone, Mark Ruffalo, …
DVD
R449
R329
Discovery Miles 3 290
|